Skip To Main Content
Stacey Melquist on Muck Rack

Stacey Melquist

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Stacey Melquist’s profile

Articles by Stacey Melquist

Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial

|
By Gerald Watts, Russell Scott, David Sullivan, John Baker, Peter M Clifton, James Hamilton, Bruce Given, Stacey Melquist, Rong Zhou, Daniel Gaudet, Ira J. Goldberg, Joshua W. Knowles, Nicholas J. Leeper, Robert A. Hegele, Christie M. Ballantyne
| Nature Verified
Abstract Loss-of-function variants in the gene encoding angiopoietin-like protein 3 (ANGPTL3) are associated with decreased triglyceride and low-density lipoprotein cholesterol levels, as well as with lower cardiovascular risk.
Open in Who Shared Issue with article?

RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts - Nature Medicine

|
By Gerald Watts, Christian Schwabe, Joshua W. Knowles, Robert A. Hegele, Stacey Melquist
| Nature Verified
Abstract Elevated triglycerides and non-high-density lipoprotein cholesterol (HDL-C) are risk factors for atherosclerotic cardiovascular disease (ASCVD). ARO-ANG3 is an RNA interference therapy that targets angiopoietin-like protein 3 (ANGPTL3), a regulator of lipoprotein metabolism.
Open in Who Shared Issue with article?
Show More